Study of DXC014 for advanced solid tumors
Part of Cancer, Kidney & urinary, Lungs & breathing, Skin clinical trials.
This trial tests DXC014, a new drug, in people with advanced solid tumors, including prostate cancer. It aims to see if the drug is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced prostate cancer or another advanced solid tumor that has not responded to standard treatments.
- You are 18 or older (75 or younger for most cancers, but any age for prostate cancer).
- You can perform daily activities with little or no help (ECOG 0-1).
- Your cancer has at least one spot that can be seen on a scan (measurable lesion), or for prostate cancer, spread to other parts of the body.
- You have adequate organ function, such as blood counts, liver, and kidney tests within certain limits.
- You agree to use effective contraception for 6 months after the last dose.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called DXC008 for people with advanced solid tumors, including prostate cancer, that have not responded to standard treatments. The goal is to see if it can help shrink tumors or slow their growth.
This trial tests a new drug called DXC006, combined with either immunotherapy (checkpoint inhibitors) or platinum-based chemotherapy, for patients with small cell lung cancer. The goal is to see if this combination works better than standard treatments.
This trial tests a new drug, MDX2001, for people with advanced solid tumors that have spread. The study aims to find the best dose and see how well it works.
This trial tests a new combination treatment (HC010) for people with advanced solid tumors that have spread or cannot be removed by surgery. It aims to see if the drug is safe and effective.
This trial tests a new drug called XNW29016 for people with advanced cancer that has stopped responding to standard treatments. It aims to see if the drug can shrink tumors or slow their growth.
This early trial tests whether JCXH-212 alone, or with toripalimab (an immunotherapy drug), is safe and tolerable in people with advanced solid cancers. It also looks at whether treatment can help by targeting tumor “neoantigens” found in your tumor tissue.
Hear when a new Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.